HomeIndustryGetting Ready for the Bounce: Mereo BioPharma Group plc (MREO) Stock

Getting Ready for the Bounce: Mereo BioPharma Group plc (MREO) Stock

Cantor Fitzgerald raised the price target for the Mereo BioPharma Group plc (NASDAQ:MREO) stock to “an Overweight”. The rating was released on August 12, 2022, according to finviz. The research report from Needham has initiated the stock to Buy, with a price target set at $10.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Mereo BioPharma Group plc (NASDAQ:MREO) raised 5.15% to close Monday’s market session at $1.02, higher as compared to yesterday’s close. The stock price fluctuated between $0.902 and $1.17 throughout the trading session with the volume trading being 2325531 shares, which represented a significant variation when compared to the three months average volume of 641.87K shares. The firm’s stock price fluctuated 14.90% within the last five trades and 92.45% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -34.62% in the last 6 months and 4.51% was added to its value over the previous 3 months. MREO stock is trading at a margin of 33.68%, 33.91% and 8.99% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


As of the close of trading, MREO deals in the Healthcare domain. The stock is trading -44.86 percent below its 52-week high and 238.87 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -49.6. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Mereo BioPharma Group plc’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $127.49 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Mereo BioPharma Group plc (NASDAQ:MREO) is 9.27. The firm managed a Price-to-Book ratio of 1.71, which equates the market value of a stock with its book value.



Please enter your comment!
Please enter your name here

Recent Post